322 related articles for article (PubMed ID: 15390358)
1. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
2. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
6. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of CAMPATH-1H in skeletal tumours.
Fritsche-Guenther R; Gruetzkau A; Noske A; Melcher I; Schaser KD; Schlag PM; Kasper HU; Krenn V; Sers C
Histopathology; 2010 Dec; 57(6):851-61. PubMed ID: 21166699
[TBL] [Abstract][Full Text] [Related]
8. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
9. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Albitar M; Do KA; Johnson MM; Giles FJ; Jilani I; O'Brien S; Cortes J; Thomas D; Rassenti LZ; Kipps TJ; Kantarjian HM; Keating M
Cancer; 2004 Sep; 101(5):999-1008. PubMed ID: 15329909
[TBL] [Abstract][Full Text] [Related]
10. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
[TBL] [Abstract][Full Text] [Related]
11. Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG; Hallek M
Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
[TBL] [Abstract][Full Text] [Related]
12. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
[TBL] [Abstract][Full Text] [Related]
13. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
14. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
Dumont FJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
[TBL] [Abstract][Full Text] [Related]
15. CD52 expression in hairy cell leukemia.
Quigley MM; Bethel KJ; Sharpe RW; Saven A
Am J Hematol; 2003 Dec; 74(4):227-30. PubMed ID: 14635201
[TBL] [Abstract][Full Text] [Related]
16. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia.
Auffermann-Gretzinger S; Eger L; Schetelig J; Bornhäuser M; Heidenreich F; Ehninger G
Transplantation; 2007 May; 83(9):1268-72. PubMed ID: 17496545
[TBL] [Abstract][Full Text] [Related]
18. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab.
Ravandi F; O'Brien S
Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
[TBL] [Abstract][Full Text] [Related]
20. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]